We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Elevated Levels of Vitamin B12 May Indicate Cancer Risk

By LabMedica International staff writers
Posted on 05 Dec 2013
Print article
Image: Blood slide from a patient with polycythemia vera associated with excess vitamin B12 levels (Photo courtesy of Dr. Ulrich Josef Woermann).
Image: Blood slide from a patient with polycythemia vera associated with excess vitamin B12 levels (Photo courtesy of Dr. Ulrich Josef Woermann).
A substantial proportion of patients referred for plasma vitamin B12 (cobalamin [Cbl]) measurement present with high Cbl levels, which have been reported in patients with different cancer types.

Vitamin B12 is essential for maintaining healthy bodily function, but higher than normal levels using a reference range of 200 pmol/L to 600 pmol/L may indicate that a patient is at risk of developing certain cancers.

Scientists at the Aarhus University Hospital (Denmark) conducted a cohort study using population-based Danish medical registries. They reviewed the records of 333,667 patients without cancer who had been referred for Cbl testing to estimate the incidence of cancer in this population from 1998 to 2010. Patients referred for Cbl measurement with levels greater than the lower reference limit of equal to or greater than 200 pmol/L were identified from the population.

Of the patients included in the study, 19,665 (6%) had levels greater than the upper reference limit of greater than 600 pmol/L. The total number of person-years of follow-up was 1,421,512 and median follow-up time was 3.5 years. The median age was 55.1 years. The distribution of outpatients and inpatients was 276,229 (83%) and 57,438 (17%), respectively. A total of 22,652 (7%) patients in the study cohort subsequently developed cancer during the period from 1998 to 2010.

The investigators found that the risk of cancer overall increased with higher Cbl levels, especially during the first year after measurement and for those with levels greater than 800 pmol/L. They also found that after five years of follow-up, the risk for hematological and alcohol and smoking-related cancers remained high for those with levels greater than 800 pmol/L. The cancer risk remained elevated after the first year of follow-up for liver, pancreatic, lung cancer, and myeloid malignancies, with highest standardized incidence ratios observed for patients with Cbl levels greater than 800 pmol/L.

The authors concluded that high plasma Cbl levels increased the risk of subsequently diagnosed cancer, mostly within the first year of follow-up. However, this association was not present for all cancer types. Although their results may have clinical implications for interpreting high Cbl levels, further studies are warranted to examine the possible diagnostic value of high plasma Cbl levels. The study was published on November 18, 2013, in the Journal of the National Cancer Institute.

Related Links:

Aarhus University Hospital


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
cTnI/CK-MB/Myo Test
Finecare cTnI/CK-MB/Myo Rapid Quantitative Test
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.